小细胞肺癌脑转移患者启动全脑放疗的时间间隔
基于美国国家癌症数据库(2004-2016)分析1082例接受30 Gy/10次全脑放疗的小细胞肺癌脑转移患者,比较化疗启动后3-14天(早期)与15-90天(晚期)开始全脑放疗的预后。早期组中位总生存8.7个月,晚期组7.5个月(HR 1.165,P=.008),多因素分析中早期全脑放疗为有利预后因素。
要点
- 早期全脑放疗组中位总生存8.7个月,晚期组7.5个月(HR 1.165,P=.008)
- 多因素分析中早期全脑放疗(P=.02)、女性(P=.045)、私人保险(P=.04)为有利预后因素
- 较长的诊断至开始全身治疗时间间隔可预测更晚的全脑放疗
核心结论
- 接受早期全脑放疗的小细胞肺癌脑转移患者相比晚期全脑放疗患者有适度总生存改善。
- 作者认为即使没有紧急全脑放疗指征,也应向脑转移患者提供早期全脑放疗。
研究设计与样本
- 查询美国国家癌症数据库(2004-2016),纳入接受30 Gy/10次全脑放疗的小细胞肺癌脑转移患者。
- 按化疗启动后3-14天(早期全脑放疗组,587例,54%)与15-90天(晚期全脑放疗组,495例,46%)分组比较。
主要发现
- 早期全脑放疗组从开始化疗至开始全脑放疗的中位时间为7天(四分位距5-10天),晚期组为34天(四分位距21-57天)。
- 二元逻辑回归分析显示,诊断至开始全身治疗的时间间隔较长可预测更晚的全脑放疗。
- 早期全脑放疗组中位总生存8.7个月,晚期组7.5个月(HR 1.165;P=.008)。
- 多因素分析中,早期全脑放疗(P=.02)、女性(P=.045)、私人保险(P=.04)为总生存的有利预后因素。
- 多因素分析中,年龄较大(P=.006)为总生存的不利预后因素。
关键数值与推荐
- 全脑放疗方案为30 Gy分10次。
- 早期全脑放疗定义为化疗启动后3-14天开始全脑放疗。
- 晚期全脑放疗定义为化疗启动后15-90天开始全脑放疗。
- 总生存定义为从诊断至死亡的天数。
临床怎么用
- 作者认为即使没有紧急全脑放疗指征,也应向脑转移患者提供早期全脑放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with small cell lung cancer (SCLC) who have brain metastases require whole-brain radiation therapy (WBRT). When there is no emergent indication for WBRT, patients may receive systemic therapy first and WBRT afterward. In scenarios when systemic therapy is initiated first, it has not been previously investigated whether delaying WBRT is harmful. METHODS AND MATERIALS: The National Cancer Database was queried (2004-2016) for patients with SCLC with brain metastases who received 30 Gy in 10 fractions of WBRT. Patients were divided into groups based on whether they received early WBRT (3-14 days after initiation of chemotherapy) or late WBRT (15-90 days after initiation of chemotherapy). Demographic and clinicopathologic categorical variables were compared between those who had early WBRT (3-14 days) and those who had late WBRT (15-90 days). Factors predictive for late WBRT were determined. Overall survival (OS), which was defined as days from diagnosis to death, was evaluated and variables prognostic for OS were determined. RESULTS: A total of 1082 patients met selection criteria; 587 (54%) had early WBRT and 495 (46%) received late WBRT. Groups were similarly distributed aside from days from initiating chemotherapy to initiating WBRT (P < .001). The early WBRT group had a median of 7 days (interquartile range [IQR], 5-10 days) from initiating chemotherapy to initiating WBRT and the late WBRT group had a median of 34 days (IQR, 21-57 days). On binary logistic regression analysis, a longer time interval between diagnosis and the start of systemic therapy was predictive for later WBRT. Median OS was 8.7 months for early WBRT and 7.5 months for late WBRT (hazard ratio [HR], 1.165; P = .008). Early WBRT (P = .02), female sex (P = .045), and private insurance (P = .04) were favorable prognostic factors for OS on multivariable analysis, whereas older age (P = .006) was an unfavorable prognostic factor. CONCLUSIONS: Patients with SCLC and brain metastases who received early WBRT were found to have a modest improvement in OS compared with patients who received late WBRT. These findings suggest that early WBRT should be offered to patients who have brain metastases, even in the absence of an indication for emergent WBRT.
引用
- Chevli N, Hunt A, Haque W, et al. Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis. Adv Radiat Oncol. 2021. PMID: 34934862. doi:10.1016/j.adro.2021.100783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。